drugset / Trial / NCT00464334

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

NCT00464334

Phase 1 Completed 86 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindDiagnostic

Summary

The purpose of this study is to test the safety, tolerability and the immune response to an investigational vaccine, V950, with or without ISCOMATRIX™ (IMX).

Timeline

Start
2007-03
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ISCOMATRIX Unknown 0 ug Intramuscular
Subject ISCOMATRIX Unknown 16 ug Intramuscular
Subject ISCOMATRIX Unknown 47 ug Intramuscular
Subject ISCOMATRIX Unknown 94 ug Intramuscular
Subject V950 Vaccine 0.5 ug Intramuscular
Subject V950 Vaccine 5 ug Intramuscular
Subject V950 Vaccine 50 ug Intramuscular

Indications